E3 Ubiquitin Protein Ligase Mdm2 - Pipeline Review, H1 2020
E3 Ubiquitin Protein Ligase Mdm2 - Pipeline Review, H1 2020
SUMMARY
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - E3 ubiquitin-protein ligase Mdm2 is a protein encoded by the MDM2 gene. It acts as an ubiquitin ligase E3 toward itself and ARRB1. It permits the nuclear export of p53/TP53. It promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein. It inhibits DAXX-mediated apoptosis by inducing its ubiquitination and degradation.
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) pipeline Target constitutes close to 29 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 8, 2, 8 and 2 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 4 and 3 molecules, respectively.
Report covers products from therapy areas Oncology, Ophthalmology, Musculoskeletal Disorders and Toxicology which include indications Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Liposarcoma, Lymphoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Glioblastoma Multiforme (GBM), Leukemia, Metastatic Breast Cancer, Myelodysplastic Syndrome, Osteosarcoma, Soft Tissue Sarcoma, Metastatic Melanoma, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Adenoid Cystic Carcinoma (ACC), B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), Brain Tumor, Breast Cancer, Chemotherapy Induced Myelosuppression, Colorectal Cancer, Dedifferentiated Liposarcoma, Diffuse Large B-Cell Lymphoma, Dry (Atrophic) Macular Degeneration, Essential Thrombocythemia, Follicular Lymphoma, Hepatic (Liver) Tumor, Hepatocellular Carcinoma, Lung Cancer, Melanoma, Merkel Cell Carcinoma, Metastatic Brain Tumor, Metastatic Colorectal Cancer, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Myelofibrosis, Neuroblastoma, Non-Small Cell Lung Cancer, Osteoarthritis, Pancreatic Cancer, Primary Myelofibrosis, Proliferative Vitreoretinopathy (PVR), Retinoblastoma, Salivary Gland Cancer, Sarcomas, Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Well Differentiated Liposarcoma.
The latest report E3 Ubiquitin Protein Ligase Mdm2 - Pipeline Review, H1 2020, outlays comprehensive information on the E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - E3 ubiquitin-protein ligase Mdm2 is a protein encoded by the MDM2 gene. It acts as an ubiquitin ligase E3 toward itself and ARRB1. It permits the nuclear export of p53/TP53. It promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein. It inhibits DAXX-mediated apoptosis by inducing its ubiquitination and degradation.
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) pipeline Target constitutes close to 29 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 8, 2, 8 and 2 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 4 and 3 molecules, respectively.
Report covers products from therapy areas Oncology, Ophthalmology, Musculoskeletal Disorders and Toxicology which include indications Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Liposarcoma, Lymphoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Glioblastoma Multiforme (GBM), Leukemia, Metastatic Breast Cancer, Myelodysplastic Syndrome, Osteosarcoma, Soft Tissue Sarcoma, Metastatic Melanoma, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Adenoid Cystic Carcinoma (ACC), B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), Brain Tumor, Breast Cancer, Chemotherapy Induced Myelosuppression, Colorectal Cancer, Dedifferentiated Liposarcoma, Diffuse Large B-Cell Lymphoma, Dry (Atrophic) Macular Degeneration, Essential Thrombocythemia, Follicular Lymphoma, Hepatic (Liver) Tumor, Hepatocellular Carcinoma, Lung Cancer, Melanoma, Merkel Cell Carcinoma, Metastatic Brain Tumor, Metastatic Colorectal Cancer, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Myelofibrosis, Neuroblastoma, Non-Small Cell Lung Cancer, Osteoarthritis, Pancreatic Cancer, Primary Myelofibrosis, Proliferative Vitreoretinopathy (PVR), Retinoblastoma, Salivary Gland Cancer, Sarcomas, Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Well Differentiated Liposarcoma.
The latest report E3 Ubiquitin Protein Ligase Mdm2 - Pipeline Review, H1 2020, outlays comprehensive information on the E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.)
- The report reviews E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics and enlists all their major and minor projects
- The report assesses E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Overview
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Therapeutics Development
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Therapeutics Assessment
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Companies Involved in Therapeutics Development
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Drug Profiles
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Dormant Products
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Discontinued Products
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Product Development Milestones
Appendix
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Overview
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Therapeutics Development
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Therapeutics Assessment
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Companies Involved in Therapeutics Development
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Drug Profiles
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Dormant Products
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Discontinued Products
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Aileron Therapeutics Inc, H1 2020
Pipeline by Amgen Inc, H1 2020
Pipeline by Ascentage Pharma Group International, H1 2020
Pipeline by Astex Pharmaceuticals Inc, H1 2020
Pipeline by Astex Therapeutics Ltd, H1 2020
Pipeline by Boehringer Ingelheim International GmbH, H1 2020
Pipeline by Daiichi Sankyo Co Ltd, H1 2020
Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Pipeline by Focal Point Pharmaceuticals Inc, H1 2020
Pipeline by Kartos Therapeutics Inc, H1 2020
Pipeline by Merck & Co Inc, H1 2020
Pipeline by MiRx Pharmaceuticals LLC, H1 2020
Pipeline by Novartis AG, H1 2020
Pipeline by Oncopia Therapeutics LLC, H1 2020
Pipeline by Seak Therapeutics LLC, H1 2020
Pipeline by Unity Biotechnology Inc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020
Discontinued Products, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Aileron Therapeutics Inc, H1 2020
Pipeline by Amgen Inc, H1 2020
Pipeline by Ascentage Pharma Group International, H1 2020
Pipeline by Astex Pharmaceuticals Inc, H1 2020
Pipeline by Astex Therapeutics Ltd, H1 2020
Pipeline by Boehringer Ingelheim International GmbH, H1 2020
Pipeline by Daiichi Sankyo Co Ltd, H1 2020
Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Pipeline by Focal Point Pharmaceuticals Inc, H1 2020
Pipeline by Kartos Therapeutics Inc, H1 2020
Pipeline by Merck & Co Inc, H1 2020
Pipeline by MiRx Pharmaceuticals LLC, H1 2020
Pipeline by Novartis AG, H1 2020
Pipeline by Oncopia Therapeutics LLC, H1 2020
Pipeline by Seak Therapeutics LLC, H1 2020
Pipeline by Unity Biotechnology Inc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020
Discontinued Products, H1 2020 (Contd..1), H1 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Aileron Therapeutics Inc
Amgen Inc
Ascentage Pharma Group International
Astex Pharmaceuticals Inc
Astex Therapeutics Ltd
Boehringer Ingelheim International GmbH
Daiichi Sankyo Co Ltd
F. Hoffmann-La Roche Ltd
Focal Point Pharmaceuticals Inc
Kartos Therapeutics Inc
Merck & Co Inc
MiRx Pharmaceuticals LLC
Novartis AG
Oncopia Therapeutics LLC
Seak Therapeutics LLC
Unity Biotechnology Inc
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Aileron Therapeutics Inc
Amgen Inc
Ascentage Pharma Group International
Astex Pharmaceuticals Inc
Astex Therapeutics Ltd
Boehringer Ingelheim International GmbH
Daiichi Sankyo Co Ltd
F. Hoffmann-La Roche Ltd
Focal Point Pharmaceuticals Inc
Kartos Therapeutics Inc
Merck & Co Inc
MiRx Pharmaceuticals LLC
Novartis AG
Oncopia Therapeutics LLC
Seak Therapeutics LLC
Unity Biotechnology Inc
